Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Archives of Cardiovascular Diseases|July 27, 2010
Impact of polyvascular disease on baseline characteristics, management and mortality in acute myocardial infarction. The Alliance projectAnouk Meizels, David Messika Zeitoun, Vincent Bataille, et al.
Expert Opinion on Pharmacotherapy|May 31, 2006
Selective and specific I(f) inhibition: new perspectives for the treatment of stable anginaKim Fox
Nature Reviews. Cardiology|May 27, 2016
Heart rate reduction in coronary artery disease and heart failureRoberto Ferrari, Kim Fox
Drugs|March 12, 2009
Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' storyRoberto Ferrari, Kim Fox
The American Journal of Cardiology|April 11, 2003
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study)Gilles Montalescot, Claire Bal-dit-Sollier, Daniela Chibedi, et al.
Advances in Cardiology|August 29, 2006
Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowingGaetano Antonio Lanza, Kim Fox, Filippo Crea
Journal of Cardiac Failure|March 2, 2026
Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients with Diabetes and Heart Failure: A SOLOIST-WHF Ancillary StudyAnis Ismail, Grace Erne, Alexi Vasbinder, et al.
European Heart Journal|August 15, 2006
Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?Kim Fox, Roberto Ferrari, Salim Yusuf, et al.
Circulation|February 20, 2003
Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trialJeffrey S Borer, Kim Fox, Patrice Jaillon, et al.
American Heart Journal|October 31, 2006
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) studyKim Fox, Roberto Ferrari, Michal Tendera, et al.
Pageof 8